Company / PP&E (Net)
IGC Pharma, Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$3.2M
FY2025
5-year range
$3.2M / $10.8M
FY2021-FY2025
Trend
-12.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has declined for 4 consecutive years, from $11M in FY2021 to $3M in FY2025.
Based on SEC 10-K filings.
$3M in FY2025 with a 5-year CAGR of -19.9%.
Declined from $8M to $3M over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -30.1%
- 5-Year CAGR
- -19.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- IGC Pharma, Inc.'s pp&e (net) has declined for 4 consecutive years.
- 5-year CAGR of -19.9%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 12.9% year-over-year.
- Peak pp&e (net) was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -13.04 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.2M | -12.9% |
| FY2024 | $3.7M | -55.0% |
| FY2023 | $8.2M | -12.8% |
| FY2022 | $9.4M | -13.1% |
| FY2021 | $10.8M | +10.8% |
| FY2020 | $9.8M | +66.2% |
| FY2019 | $5.9M | -5.6% |
| FY2018 | $6.2M | +553.8% |
| FY2017 | $953.9K | -86.5% |
| FY2016 | $7.1M | -9.1% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026